Developer docs
API playgroundTry for free, no card

Search company profiles

Bormioli Pharma

Full company profile

uuid0008axn

Namestring
Bormioli Pharma
Legal namestring
Bormioli Pharma S.p.A.
Company typeenum
Private
Founded yearint
1825
Descriptiontext

Bormioli Pharma S.p.A. is a pharmaceutical primary packaging manufacturer headquartered in Parma, Italy, with a registered office in Milan and operating subsidiaries in France, the United States (Delaware), Germany, and China (Shanghai). The company is a wholly-owned subsidiary of Gerresheimer AG, a Düsseldorf-based multinational that distributes the portfolio globally as part of its pharma and biotech systems offering. Bormioli Pharma produces glass containers (Flint I, Amber I, Flint III, Amber III) and plastic containers (PP, HDPE, LDPE, PE) for injection, oral solid, oral liquid, chromatography, and reagent applications, alongside medical devices such as measuring cups (AF0975 series) and dual chamber reconstitution kits marketed under the AccuRec, ActiveRec, and EasyRec sub-brands, with ActiveRec incorporating proprietary DRIEX integrated technology. Manufacturing is qualified to ISO 9001, ISO 15378 (GMP for pharma primary packaging), ISO 13485 (medical devices), ISO 45001, and ISO 14001, with medical device products compliant with EU Regulation 2017/745.

The company sells exclusively B2B to pharmaceutical and biotechnology manufacturers through a quote-based enterprise field sales motion, with pricing negotiated per multi-year contract based on volume and customization requirements; no retail channel or public pricing exists. Customers engage via the company's website to scope requirements, with a wishlist-driven inquiry flow feeding directly to the sales team. Sub-brand and SKU breadth — 685+ products — supports both standardized catalog orders and engineered custom packaging programs. Distribution is executed through Gerresheimer's global sales network rather than independent channels, embedding Bormioli Pharma inside the parent's compliance framework (Italian Legislative Decree 231/2001, EU Whistleblowing Directive 2019/1937, anti-corruption, antitrust, Code of Ethics) and ESG policy aligned with UN Agenda 2030 SDGs. The combined manufacturing capability, regulatory depth, and Gerresheimer-parent distribution are the structural basis of the company's positioning in pharma primary packaging.

Short descriptiontext

Bormioli Pharma is an Italian pharmaceutical primary packaging manufacturer — wholly-owned by Gerresheimer AG — producing glass and plastic containers, medical devices, and dual chamber reconstitution kits for global pharmaceutical and biotech manufacturers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersMilan, Italy
HQ citystring
Milan
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical packaging, primary packaging containers, dual chamber kits, medical devices packaging, drug delivery systems
Industry4 codes
1Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules)
CodeIMALAIAAPrimaryYes
2Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes)
CodeIMALAEABPrimaryNo
3Pharmaceutical & Medical Plastic Packaging Manufacturing
CodeIMANAEAKPrimaryNo
4Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges)
CodeIMALAIAEPrimaryNo
NAICS code2 codes
  • Glass Container Manufacturing327213
  • Plastics Bottle Manufacturing326160
SIC code3 codes
  • Glass Containers3221
  • Glass Products, Made Of Purchased Glass3231
  • Miscellaneous Plastics Products3080
Product category
Pharmaceutical Primary Packaging
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Primary Packaging Sales
TypeHardware Sales
Description

Direct sale of pharmaceutical packaging products including glass containers, plastic containers, dual chamber kits, medical devices, and pharmaceutical dispensers to pharmaceutical and biotech companies.

bormiolipharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Quote-based enterprise pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is not publicly disclosed. Customers submit inquiries through the website contact form specifying product required and annual supply quantity. Sales team provides customized quotes.

bormiolipharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1AccuRec
Description

Dual chamber kit product line for oral reconstitution applications

bormiolipharma.com
+2 more records
Core offering1 text field

Bormioli Pharma manufactures pharmaceutical primary packaging including glass containers (Flint and Amber Types I and III) and plastic containers (PP, HDPE, LDPE, PE) for injection, oral solid, chromatography, and reagent applications. The company also produces dual chamber reconstitution kits (AccuRec, ActiveRec, EasyRec) for oral pharmaceuticals and medical devices such as measuring cups and pharmaceutical dispensers. Products are sold directly to pharmaceutical and biotech manufacturers as part of the Gerresheimer Group portfolio.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Bormioli Pharma is a pharmaceutical primary packaging manufacturer offering a comprehensive portfolio of 685 products integrated into the Gerresheimer Group. The product range includes glass and plastic containers for various routes of administration (Injection, Oral Solid, Chromatography, Reagents) available in Flint and Amber glass types, medical devices such as measuring cups (AF0975 series) for oral liquid and oral reconstitution, and dual chamber reconstitution kits (AccuRec and ActiveRec systems) for pharmaceutical preparations. All products are designed for the pharma and biotech industry with focus on safe and convenient medicine administration.

Product and service6 records
1Pharmaceutical Containers
CategoryPharmaceutical Primary Packaging
Description

Pharmaceutical glass and plastic containers available in Flint and Amber glass types (Type I and Type III) for various routes of administration including Injection, Oral Solid, Chromatography, and Reagents. Designed for pharmaceutical and biotech manufacturers requiring primary packaging.

2AF0975 OL Measuring Cup
CategoryMedical Devices
Description

Medical device measuring cup for oral liquid administration, made of PP plastic with PFP 28 screw neck finish. Features level marks from 2.5ml to 10ml. EU Regulation 2017/745 compliant.

3AF0975 OR Measuring Cup
CategoryMedical Devices
Description

Medical device measuring cup for oral reconstitution, made of PP plastic with PFP 28 screw neck finish. Features level marks from 2.5ml to 10ml. EU Regulation 2017/745 compliant.

4AccuRec Kit (4cc)
CategoryDrug Delivery Systems
Description

Dual chamber kit for oral reconstitution composed of Cap AM1586, Plug AM1583, and Plunger AM1587. Available in 4cc nominal capacity using PP, HDPE, and LDPE materials. Enables separate storage of powder and liquid until time of administration.

5ActiveRec Kit 0.5cc
CategoryDrug Delivery Systems
Description

Dual chamber kit for oral reconstitution using the EasyRec system. Composition includes Cap AM1299, Plug AM1376, and Plunger AM1567. Features PP, HDPE, LDPE, and DRIEX materials.

6ActiveRec Kit 0.8cc
CategoryDrug Delivery Systems
Description

Dual chamber kit for oral reconstitution using the EasyRec system. Composition includes Cap AM1299, Plug AM1376, and Plunger AM1599. Features PP, HDPE, LDPE, and DRIEX materials.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Bormioli Pharma is part of the Gerresheimer Group, a global provider of systems and solutions for the pharma and biotech industry. Bormioli Pharma's products are integrated into Gerresheimer's portfolio, contributing to the most complete and high-quality offering in the pharmaceutical packaging industry. Gerresheimer AG, headquartered in Düsseldorf, Germany, sets overarching compliance framework and organizational standards for its global operations.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bormioli Pharma

Pharmaceutical Primary Packagingbormiolipharma.com

Bormioli Pharma is an Italian pharmaceutical primary packaging manufacturer — wholly-owned by Gerresheimer AG — producing glass and plastic containers, medical devices, and dual chamber reconstitution kits for global pharmaceutical and biotech manufacturers.

What Bormioli Pharma does

Bormioli Pharma S.p.A. is a pharmaceutical primary packaging manufacturer headquartered in Parma, Italy, with a registered office in Milan and operating subsidiaries in France, the United States (Delaware), Germany, and China (Shanghai). The company is a wholly-owned subsidiary of Gerresheimer AG, a Düsseldorf-based multinational that distributes the portfolio globally as part of its pharma and biotech systems offering. Bormioli Pharma produces glass containers (Flint I, Amber I, Flint III, Amber III) and plastic containers (PP, HDPE, LDPE, PE) for injection, oral solid, oral liquid, chromatography, and reagent applications, alongside medical devices such as measuring cups (AF0975 series) and dual chamber reconstitution kits marketed under the AccuRec, ActiveRec, and EasyRec sub-brands, with ActiveRec incorporating proprietary DRIEX integrated technology. Manufacturing is qualified to ISO 9001, ISO 15378 (GMP for pharma primary packaging), ISO 13485 (medical devices), ISO 45001, and ISO 14001, with medical device products compliant with EU Regulation 2017/745.

The company sells exclusively B2B to pharmaceutical and biotechnology manufacturers through a quote-based enterprise field sales motion, with pricing negotiated per multi-year contract based on volume and customization requirements; no retail channel or public pricing exists. Customers engage via the company's website to scope requirements, with a wishlist-driven inquiry flow feeding directly to the sales team. Sub-brand and SKU breadth — 685+ products — supports both standardized catalog orders and engineered custom packaging programs. Distribution is executed through Gerresheimer's global sales network rather than independent channels, embedding Bormioli Pharma inside the parent's compliance framework (Italian Legislative Decree 231/2001, EU Whistleblowing Directive 2019/1937, anti-corruption, antitrust, Code of Ethics) and ESG policy aligned with UN Agenda 2030 SDGs. The combined manufacturing capability, regulatory depth, and Gerresheimer-parent distribution are the structural basis of the company's positioning in pharma primary packaging.

Bormioli Pharma firmographics

Firmographics
Name
Bormioli Pharma
Legal name
Bormioli Pharma S.p.A.
Website
https://bormiolipharma.com
Company type
Private
Founded year
1825
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Bormioli Pharma is an Italian pharmaceutical primary packaging manufacturer — wholly-owned by Gerresheimer AG — producing glass and plastic containers, medical devices, and dual chamber reconstitution kits for global pharmaceutical and biotech manufacturers.
Ownership category
akta.pro rank

Bormioli Pharma industry classification

Industry
Product category
Pharmaceutical Primary Packaging
NAICS
Glass Container Manufacturing (327213), Plastics Bottle Manufacturing (326160)
SIC
Glass Containers (3221), Glass Products, Made Of Purchased Glass (3231), Miscellaneous Plastics Products (3080)
akta.pro primary industry
Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules) (IMALAIAA)
akta.pro secondary industries
Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes) (IMALAEAB), Pharmaceutical & Medical Plastic Packaging Manufacturing (IMANAEAK), Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges) (IMALAIAE)

Keywords

  • Pharmaceutical packaging
  • Primary packaging containers
  • Dual chamber kits
  • Medical devices packaging
  • Drug delivery systems

Where Bormioli Pharma is headquartered

Location

Headquarters

HQ city
Milan
HQ country
Italy
HQ region
Europe

Offices6 records

Markets served

Bormioli Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Pharmaceutical Primary Packaging Sales: Direct sale of pharmaceutical packaging products including glass containers, plastic containers, dual chamber kits, medical devices, and pharmaceutical dispensers to pharmaceutical and biotech companies.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based enterprise pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Bormioli Pharma product offering

Product offering

Core offering

Bormioli Pharma manufactures pharmaceutical primary packaging including glass containers (Flint and Amber Types I and III) and plastic containers (PP, HDPE, LDPE, PE) for injection, oral solid, chromatography, and reagent applications. The company also produces dual chamber reconstitution kits (AccuRec, ActiveRec, EasyRec) for oral pharmaceuticals and medical devices such as measuring cups and pharmaceutical dispensers. Products are sold directly to pharmaceutical and biotech manufacturers as part of the Gerresheimer Group portfolio.

Product overview

Bormioli Pharma is a pharmaceutical primary packaging manufacturer offering a comprehensive portfolio of 685 products integrated into the Gerresheimer Group. The product range includes glass and plastic containers for various routes of administration (Injection, Oral Solid, Chromatography, Reagents) available in Flint and Amber glass types, medical devices such as measuring cups (AF0975 series) for oral liquid and oral reconstitution, and dual chamber reconstitution kits (AccuRec and ActiveRec systems) for pharmaceutical preparations. All products are designed for the pharma and biotech industry with focus on safe and convenient medicine administration.

Differentiator

Problem solved

Functional benefit

Brands

  • AccuRec: Dual chamber kit product line for oral reconstitution applications
  • ActiveRec
  • EasyRec

Products and services

  • Pharmaceutical Containers Pharmaceutical glass and plastic containers available in Flint and Amber glass types (Type I and Type III) for various routes of administration including Injection, Oral Solid, Chromatography, and Reagents. Designed for pharmaceutical and biotech manufacturers requiring primary packaging.
  • AF0975 OL Measuring Cup Medical device measuring cup for oral liquid administration, made of PP plastic with PFP 28 screw neck finish. Features level marks from 2.5ml to 10ml. EU Regulation 2017/745 compliant.
  • AF0975 OR Measuring Cup Medical device measuring cup for oral reconstitution, made of PP plastic with PFP 28 screw neck finish. Features level marks from 2.5ml to 10ml. EU Regulation 2017/745 compliant.
  • AccuRec Kit (4cc) Dual chamber kit for oral reconstitution composed of Cap AM1586, Plug AM1583, and Plunger AM1587. Available in 4cc nominal capacity using PP, HDPE, and LDPE materials. Enables separate storage of powder and liquid until time of administration.
  • ActiveRec Kit 0.5cc Dual chamber kit for oral reconstitution using the EasyRec system. Composition includes Cap AM1299, Plug AM1376, and Plunger AM1567. Features PP, HDPE, LDPE, and DRIEX materials.
  • ActiveRec Kit 0.8cc Dual chamber kit for oral reconstitution using the EasyRec system. Composition includes Cap AM1299, Plug AM1376, and Plunger AM1599. Features PP, HDPE, LDPE, and DRIEX materials.

Companies that use Bormioli Pharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Bormioli Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Bormioli Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Gerresheimer GroupcoreStrategic or Co-development PartnerBormioli Pharma is part of the Gerresheimer Group, a global provider of systems and solutions for the pharma and biotech industry. Bormioli Pharma's products are integrated into Gerresheimer's portfolio, contributing to the most complete and high-quality offering in the pharmaceutical packaging industry. Gerresheimer AG, headquartered in Düsseldorf, Germany, sets overarching compliance framework and organizational standards for its global operations.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Bormioli Pharma competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Bormioli Pharma social profiles

Digital presence

Bormioli Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bormioli Pharma leadership team

Management profile

Number of profiles

Profiles1 record

Bormioli Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Bormioli Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bormioli Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bormioli Pharma

What does Bormioli Pharma do?

Bormioli Pharma manufactures pharmaceutical primary packaging including glass containers (Flint and Amber Types I and III) and plastic containers (PP, HDPE, LDPE, PE) for injection, oral solid, chromatography, and reagent applications. The company also produces dual chamber reconstitution kits (AccuRec, ActiveRec, EasyRec) for oral pharmaceuticals and medical devices such as measuring cups and pharmaceutical dispensers. Products are sold directly to pharmaceutical and biotech manufacturers as part of the Gerresheimer Group portfolio.

Is Bormioli Pharma a public or private company?

Bormioli Pharma is a private company. It is classified as corporate owned and is currently operating.

When was Bormioli Pharma founded?

Bormioli Pharma was founded in 1825. It employs 1,001 to 5,000 people.

Where is Bormioli Pharma based?

Bormioli Pharma is headquartered in Milan, Italy, in the Europe region.

How does Bormioli Pharma make money?

One revenue line is on record: pharmaceutical Primary Packaging Sales.

Does Bormioli Pharma have an API?

No public API is recorded for Bormioli Pharma.

What industry is Bormioli Pharma in?

Bormioli Pharma's product category is Pharmaceutical Primary Packaging. Its primary akta.pro industry code is IMALAIAA, Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules), with a secondary code of IMALAEAB, Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes). Its NAICS code is 327213 and its SIC code is 3221.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooGerresheimer swings to €318.7m loss in 2025Gerresheimer reported a €318.7m net loss in 2025, primarily due to non-cash impairments and restructuring costs, despite a 16.6% revenue increase driven by the acquisition of Bormioli Pharma. The company expects lower revenue and EBITDA margins for 2026 and is progressing with the sale of its US subsidiary Centor to improve its financial position. Gerresheimer also rejected a takeover proposal from Silgan.Investing.comGerresheimer FY 2025 slides show governance reset amid cash flow strain By Investing.comGerresheimer AG presented its FY 2025 results on June 29, 2026, with new management completing a governance cleanup following accounting irregularities that required EUR 45 million in revenue and EUR 31 million in adjusted EBITDA restatements. The company reported negative free cash flow of EUR 86 million and significantly elevated leverage of 4.95x adjusted EBITDA, just below the 5.0x covenant threshold, driven by the December 2024 acquisition of Bormioli Pharma that added EUR 331 million in revenue but could not offset a 30% adjusted EBITDA decline in the legacy Primary Packaging Glass business. The company launched a transformation program targeting EUR 10-20 million in EBITDA improvement during 2026, with significant refinancing needs of EUR 1.9 billion maturing in 2029-2030.Investing.comEarnings call transcript: Gerresheimer Q4 2026 stock falls on weak cash flow By Investing.comGerresheimer AG reported its 2025 full-year results showing revenue of 2.3 billion euros, up 330 million euros year-over-year, though organic growth was only 0.3% as most gains came from the Bormioli Pharma acquisition. The company posted negative free cash flow of 86 million euros, adjusted EBITDA essentially flat at 384 million euros, and an EPS loss of 1.65 euros, with shares falling 3.47% following the results. Management outlined 2026 guidance expecting revenue in the lower half of the 2.3-2.4 billion euro range and continued negative free cash flow of 50-100 million euros, while focusing on the planned divestiture of Centor and debt refinancing.FinanzNachrichten.deEQS-News: Gerresheimer AG: Gerresheimer legt Jahres- und Konzernabschluss 2025 vor: Stabiler Umsatz in einem herausfordernden GeschäftsjahrGerresheimer AG published its audited 2025 annual and consolidated financial statements, reporting revenue of EUR 2.321 billion (up 16.6% year-on-year due to the first-time inclusion of Bormioli Pharma) and Adjusted EBITDA of EUR 384 million with a margin of 16.8%, down from 19.4% in 2024 on a pro-forma basis, with organic growth flat at 0.3%. The company posted a net loss of EUR 318.7 million after non-cash impairments of approximately EUR 521.5 million related to Sensile Medical AG technology projects, goodwill, and the assets of Gerresheimer Moulded Glass Chicago Inc., and will pay no dividend for 2025. For 2026, Gerresheimer forecasts revenue in the lower half of the EUR 2.3–2.4 billion range, an Adjusted EBITDA margin of 17–18%, and expects to complete the sale of its US subsidiary Centor and a debt refinancing to improve its financial position.AInvestGerresheimer sees adj. EBITDA margin of approx. 17%-18%Gerresheimer AG reported an adjusted EBITDA margin of approximately 17%-18% in its Primary Packaging Glass Division for FY 2024, impacted by ongoing destocking effects at pharmaceutical customers, though the division maintained a stable full-year margin of 19.7% with recovery signs emerging in Q4. The Plastics & Devices Division delivered stronger results at 25.7%, helping lift the company's overall adjusted EBITDA margin to 20.6% from 20.3% in 2023. The company expects the integration of Bormioli Pharma to drive profitability with a target margin of around 22% for 2025.PR NewswireDroppers Market Size Worth $61.81 Million by 2032, Exclusive Report by Maximize Market ResearchMaximize Market Research projects the global droppers market to grow from USD 43.06 billion in 2025 to USD 61.81 billion by 2032, registering a CAGR of 5.3%, driven by rising demand across healthcare, cosmetics, personal care, and vaping industries. North America currently leads the market while Asia-Pacific, particularly China, India, and ASEAN countries, is expected to dominate overall growth. Notable strategic moves include Virospack SL's majority stake acquisition by Investindustrial, Bormioli Pharma's acquisition of Remy & Geiser GmbH, and APG Pharma Packaging's launch of its fully recyclable Infinity Dropper in February 2024.EIN PresswireConsumer Packaging Market Size to Reach USD 434.62 Billion by 2032: Trends, Forecast, Demand and Competitive AnalysisMaximize Market Research reports that the Global Consumer Packaging Market was valued at USD 274.75 billion in 2024 and is projected to grow at a CAGR of 5.9%, reaching USD 434.62 billion by 2032, driven by e-commerce expansion, sustainability trends, and smart packaging adoption. Specific company developments include Amcor plc securing a European patent for its AmFiber high-barrier paper-based packaging in November 2024, Aptar Group Inc planning global expansion in 2025, and Gerresheimer AG reporting an 11.6% revenue surge and 13.1% EBITDA growth in April 2025 following its consolidation of Bormioli Pharma. North America led the market with a 34.5% revenue share in 2024, followed by Europe, as demand for eco-friendly, recyclable, and digital-enabled packaging solutions accelerates across FMCG, food, beverage, and healthcare sectors.GerresheimerGerresheimer in H1 2025: Bormioli Pharma boosts revenues and earnings, continued market influences in operating businessGerresheimer reported H1 2025 revenue of EUR 1,120.7 million, up 15.7% from the prior year period, while adjusted EBITDA rose 11.8% to EUR 210.4 million, driven primarily by the inclusion of Bormioli Pharma, which was acquired in 2024. Organically, revenues declined 2.1% and adjusted EBITDA fell 6.4% compared to pro forma H1 2024 figures, reflecting temporary weakness in cosmetics and oral liquids markets, though the company returned to organic growth in Q2 2025. The company expects stronger growth in H2 2025 based on production ramp-ups and maintained full-year guidance for 0-2% organic revenue growth and approximately 20% adjusted EBITDA margin, with a positive mid-term outlook targeting 6-9% organic revenue growth and 23-25% EBITDA margin.Fact.MRSterile Vials Market Share and Growth StatisticsThe global sterile vials market is projected to grow from USD 6.7 billion in 2025 to USD 15.1 billion by 2035, driven by rising demand for biologics, vaccines, and chronic disease treatments. Key growth regions include the United States, China, and Japan, with prominent industry players such as Corning Incorporated, Gerresheimer AG, and Bormioli Pharma S.p.A. leading the sector. Recent developments include strategic partnerships and new product launches aimed at meeting stringent regulatory standards and expanding production capacity.PharmiWeb.comGerresheimer to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group / Moulded Glass business to be strategically reviewedGerresheimer AG has signed a purchase agreement to acquire Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group, for an enterprise value of approximately EUR 800 million. This acquisition expands Gerresheimer's European presence and leads to the creation of a new Moulded Glass business unit, with the transaction expected to close in Q4 2024.